Literature DB >> 6095072

Phosphate-binding specificities of monoclonal antibodies against phosphoinositides in liposomes.

N M Wassef, F Roerdink, G M Swartz, J A Lyon, B J Berson, C R Alving.   

Abstract

Monoclonal antibodies against phosphatidylinositol phosphate were produced after injecting a mouse with liposomes containing dimyristoylphosphatidylcholine, cholesterol, phosphatidylinositol phosphate and lipid A. The antibodies raised were IgM (kappa) and their activities were assayed by complement-dependent damage to liposomes lacking lipid A but containing the rest of original immunizing mixture of lipids. Three of the four antibodies selected cross-reacted with liposomes containing phosphatidylinositol instead of phosphatidylinositol phosphate; and two of the antibodies cross-reacted with liposomes containing phosphatidylinositol diphosphate. Each of the antibodies had a phosphate-binding specificity. Each also cross-reacted with liposomes containing sulfogalactosyl ceramide, but not with liposomes containing galactosyl ceramide, or gangliosides or with liposomes containing lipid A but lacking phosphoinositides. Recognition of sulfogalactosyl ceramide probably occurred because the chemical characteristics of the sulfate group were sufficiently similar to those of phosphate to allow recognition by the antibody. The phosphate-binding specificity was further confirmed by inhibition by phosphocholine, inositol hexaphosphate, ATP, AMP and even sodium phosphate, but not by choline or inositol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095072     DOI: 10.1016/0161-5890(84)90140-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

Review 1.  The biochemistry and genetics of DNA and anti-DNA antibodies.

Authors:  B D Stollar
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

2.  Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate.

Authors:  B M Alving; B Banerji; W E Fogler; C R Alving
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

3.  Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites.

Authors:  Bruce K Brown; Nicos Karasavvas; Zoltan Beck; Gary R Matyas; Deborah L Birx; Victoria R Polonis; Carl R Alving
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

4.  Antibodies to cholesterol.

Authors:  G M Swartz; M K Gentry; L M Amende; E J Blanchette-Mackie; C R Alving
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  A fully synthetic and biochemically validated phosphatidyl inositol-3-phosphate hapten via asymmetric synthesis and native chemical ligation.

Authors:  Brent D Chandler; Anne L Burkhardt; Klaudia Foley; Courtney Cullis; Denise Driscoll; Natalie Roy D'Amore; Scott J Miller
Journal:  J Am Chem Soc       Date:  2013-12-17       Impact factor: 15.419

6.  Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines.

Authors:  Gary R Matyas; Lindsay Wieczorek; Divya Bansal; Agnes-Laurence Chenine; Eric Sanders-Buell; Sodsai Tovanabutra; Jerome H Kim; Victoria Polonis; Carl R Alving
Journal:  Biochem Biophys Res Commun       Date:  2010-10-30       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.